Spinal chemotherapy may stop brain damage from cancer treatment
NCT ID NCT06895473
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether injecting chemotherapy drugs (cytarabine, methotrexate, and hydrocortisone) into the spinal fluid can prevent severe brain side effects in people receiving CAR T-cell therapy for blood cancers. About 20-70% of CAR T patients develop neurotoxicity, which can cause confusion, seizures, or brain swelling. The study will enroll 26 adults and track how many develop serious brain symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cytarabine, methotrexate, and hydrocortisone injected into the spinal fluid
What this could lead to
If it works, this could make CAR T-cell therapy safer by preventing serious brain side effects, allowing more patients to benefit from this cancer treatment.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply to everyone. The spinal injections themselves carry risks like headache or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact